Walden Biosciences Announces Positive Topline Data from Phase 1+ Clinical Study of WAL0921 in Development for Treatment of Kidney Diseases

15 Apr 2024
www.biospace.com
Phase 1Clinical Result
Proprietary Human anti-suPAR Monoclonal Antibody Demonstrated Safety and Reduction of Circulating Free suPAR, a Cause of Kidney Disease Plans to Initiate Phase 2 Basket Study in Glomerular Kidney Diseases in 2Q24 CAMBRIDGE, Mass., April 15, 2024 (GLOBE NEWSWIRE) -- Walden Biosciences, Inc. (Walden), a private, venture-backed clinical development stage company focused on disease-modifying, transformative therapies for the treatment of kidney diseases, today announced the results from the Company’s Phase 1+ clinical study of WAL0921 in healthy subjects. WAL0921 is Walden’s first-in-class, proprietary, humanized monoclonal antibody that binds circulating free soluble urokinase plasminogen activator receptor (suPAR) and its membrane bound form, uPAR, and inhibits their pathological activity, which causes kidney diseases. Elevated levels of suPAR injure kidney tissues leading to podocytes dysfunction and associated proteinuria. The compromised kidney structure and function ultimately may lead to end-stage kidney disease requiring dialysis. “These data from our Phase 1+ study are compelling and demonstrate WAL0921’s ability to directly target and rapidly reduce free suPAR levels, and may provide a truly novel and disease-modifying approach for many kidney diseases” noted Andrew Blair, M.D., Chief Medical Officer of Walden. The Phase 1+ clinical study was a single center, placebo-controlled, single ascending dose study of WAL0921 in five cohorts that evaluated its safety, pharmacokinetics, and pharmacodynamics in 40 healthy subjects. Data from the study showed that WAL0921 was safe, well-tolerated, and demonstrated proof-of-biology through a rapid, dose-dependent reduction in free suPAR levels. “These data reinforce WAL0921’s unique mechanism that targets a key underlying pathway of kidney disease and supports our plan to rapidly advance this promising product candidate into a Phase 2 Basket study of glomerular kidney diseases in the second quarter of 2024,” stated Blaine H. McKee, Ph.D., Chief Executive Officer of Walden. About Walden Biosciences Walden Biosciences is a private, venture-backed clinical development-stage company focused on developing breakthrough, disease-modifying medicines to treat kidney diseases. Walden is applying novel, multi-disciplinary approaches that directly target the kidney to prevent damage, slow disease progression, and restore kidney function. Walden’s programs address novel targets for therapeutic intervention, directly targeting two cell types critical for kidney function: podocytes and proximal tubular cells. Dysfunction of these cells are critical hallmarks of the majority of kidney diseases. Walden’s clinical-stage program is a humanized monoclonal antibody that inhibits suPAR, a pro-inflammatory mediator that causes podocyte dysfunction and kidney disease. Walden’s second most advanced program is a small molecule that is designed to restore the function of dynamin, an enzyme responsible for the maintenance of the cytoskeletal architecture and function of podocytes and proximal tubule cells. In addition to the suPAR and dynamin programs, Walden also has a novel anti-fibrotic biologic in preclinical research. All of Walden’s programs offer the promise to deliver disease-modifying, breakthrough therapies that are readily combinable with the standard of care to transform the treatment of kidney disease. For more information, please visit . Investor Contact: Stern Investor Relations Anne Marie Fields Managing Director annemarie.fields@sternir.com Media Contacts FTI Consulting Senior Managing Director Robert Stanislaro Robert.Stanislaro@fticonsulting.com -OR- Helen O’Gorman Managing Director Helen.OGorman@fticonsulting.com
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.